Insights from 2023 ASH Annual Meeting
Leukemia
Insights from 2023 ASH Annual Meeting
Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOIA Study
FEATURING
Paolo Ghia
- 29 views
- March 27, 2024
Insights from 2023 ASH Annual Meeting
QuANTUM-First Trial - PROs in FLT3-ITD Mutated AML Receiving Quizartinib vs. Standard Chemo
FEATURING
Esther Oliva
- 34 views
- March 22, 2024
Insights from 2023 ASH Annual Meeting
Clinically-Relevant Updates in ALL in Adults From ASH 2023
FEATURING
Ryan Cassaday
- 49 views
- February 20, 2024
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of CLL - Highlights & Key Takeaways"
FEATURING
Victor Yazbeck
- 402 views
- January 24, 2024
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlights & Key Takeaways"
FEATURING
Talha Badar
- 1,310 views
- January 24, 2024
- 13
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Treatment-Naïve, Higher-Risk MDS"
FEATURING
Jacqueline Garcia
- 334 views
- December 29, 2023
- 2
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults With ND Ph- B-ALL or T-ALL"
FEATURING
Marlise R. Luskin
- 163 views
- December 29, 2023
- 2
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Venetoclax With Inotuzumab Ozogamicin for R/R ALL in Adults"
FEATURING
Marlise R. Luskin
- 16 views
- December 29, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Comparison of Venetoclax Based Treatments for Patients With R/R CLL"
FEATURING
Benjamin Heyman
- 114 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "QuANTUM-First - Safety by Treatment Phase and by Age in ND Pts With FLT3-ITD+ AML"
FEATURING
Harry P. Erba
- 67 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Primetime?"
FEATURING
Joanna Rhodes
- 306 views
- December 22, 2023
- 2
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Treatment for 1L CP-CML"
FEATURING
David Yeung
- 104 views
- December 20, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "AYAs With ALL - Treatment Approaches and Ongoing Challenges"
FEATURING
Emily Curran
- 35 views
- December 19, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients With CLL/SLL"
FEATURING
Mazyar Shadman
- 126 views
- December 19, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy After BTKis in CLL"
FEATURING
Nilanjan Ghosh
- 132 views
- December 17, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & Rituximab for the Treatment of CLL"
FEATURING
Chung-Jiah Chen
- 24 views
- December 17, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL"
FEATURING
Kerry Rogers
- 61 views
- December 17, 2023
- 1
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Quizartinib, Venetoclax, & Decitabine Triple Combination in FLT3-ITD-Mutated AML"
FEATURING
Musa Yilmaz
- 54 views
- December 15, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Regimen of CC-486 and Venetoclax For R/R AML"
FEATURING
Maria Amaya
- 147 views
- December 14, 2023